Two Johnson & Johnson drugs are planned to be included in breakthrough therapy to treat chronic hepatitis B

Text | Sunshine

On July 12, the CDE official website showed that Johnson & Johnson’s JNJ-56136379 tablets and JNJ-73763989 injections are planned to be included in the breakthrough therapy, and both are used to treat chronic hepatitis B virus infection

Chronic hepatitis B (CHB) is a chronic disease in which the hepatitis B virus continues to be infected for more than 6 months, and the liver has varying degrees of inflammation and necrosis (or) fibrosis

There are approximately 257 million chronic hepatitis B infections in the world, 68% of which are in Africa and the Western Pacific

JNJ-56136379 tablet (JNJ-379) is a hepatitis B virus nucleocapsid protein assembly inhibitor obtained by Johnson & Johnson's acquisition of Alios Bioph.

At present, the treatment of chronic hepatitis B with JNJ-56136379 tablets has been advanced to phase II clinical

Source: NextPharma

JNJ-73763989 injection (ARO-HBV, JNJ-3989) is an siRNA therapy jointly developed by Arrowhead Pharmaceuticals and Johnson & Johnson

At present, JNJ-73763989 injection treatment of chronic hepatitis B has advanced to phase II clinical

Source: NextPharma

Johnson & Johnson has carried out Phase I/II clinical trials (AROHBV1001) to study the effectiveness of triple therapy of JNJ-3989 (RNAi), JNJ-6379 (HBV capsid inhibitor) and NA